Information Provided By: 
Fly News Breaks for March 29, 2017
REGN
Mar 29, 2017 | 07:22 EDT
After FDA approved Regeneron (REGN) and Sanofi's (SNY) Dupixent, Credit Suisse analyst Alethia Young says that the pricing was higher than her expectations, but thinks that the peak opportunity is roughly around the same, remaining unchanged at $4.7B in 2025. Additionally, the analyst thinks that Regeneron/Sanofi upfront effort with payers may help early days of launch. She reiterates an Outperform rating and $485 price target on Regeneron's shares.
News For REGN From the Last 2 Days
There are no results for your query REGN
